Hyundai Motor Shares Slide After Trump Signals Higher U.S. Tariffs on South Korean Goods 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
The Maire - EuroChem Case: Three Lessons for Global Business 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability 
BASEL, Switzerland and CAMBRIDGE, Mass., May 18, 2017 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the selection of an abstract for presentation in the Presidential Symposium of the 22nd Congress of the European Hematology Association (EHA) taking place in Madrid, Spain on June 22-25, 2017.
This abstract, selected by the Scientific Program Committee as one of the five best abstracts, will highlight recent work in re-creating the natural condition of hereditary persistence of fetal hemoglobin (HPFH) that is protective in sickle cell disease and beta thalassemia. The presentation will describe the ability to re-create specific HPFH gene variants in the intended target tissue, human primary CD34+ stem cells, the effect of these gene variants at re-creating the expression of protective fetal hemoglobin and progress in developing a product ready for clinical testing.
“We are pleased to have been selected as one of the five best abstracts at the leading global conference in the field of hematology. We remain on track to file a clinical trial application by the end of 2017 and the initiation of clinical trials in Europe in 2018,” said Dr. Rodger Novak, CEO of CRISPR Therapeutics AG.
Details of the presentation are as follows:
| Title: | Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) with CRISPR/Cas9 To Treat Sickle Cell Disease (SCD) and Beta-Thalassemia (Beta-Thal) |
| Presenter: | Bill (Sven Ante) Lundberg, M.D., Chief Scientific Officer, CRISPR Therapeutics |
| Date / Time: | Friday, June 23, 4:00-4:15 PM (Central European time zone) |
| Session Title: | Presidential Symposium located in Hall A |
| Abstract: | S147 |
A copy of the EHA abstracts were made available May 18, 2016 through the EHA meeting website at www.ehaweb.org. Following the presentation, the data presented will be available under the “Investors & Media” section of the Company’s website at www.crisprtx.com and will also be webcast by the EHA.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Basel, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com.
Media Contacts: Jennifer Paganelli WCG on behalf of CRISPR 1-347-658-8290 [email protected] Investor Contact: Chris Brinzey Westwicke Partners for CRISPR 1-339-970-2843 [email protected]
